Primary Biliary Cholangitis?Hepatocellular carcinoma
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hepatocellular Carcinoma (HCC) Samples 1. Patients with a definitive diagnosis of hepatocellular carcinoma (HCC) in the TCGA database; 2. Possess complete transcriptomic expression data; 3. Have complete clinical follow-up information suitable for survival analysis (including overall survival time and survival status); 4.Samples derived from liver tumor tissue; 5. Gene expression data meet quality control standards. Primary Biliary Cholangitis (PBC) Samples 1. Patients explicitly labeled as having primary biliary cholangitis (PBC) in the GEO dataset; 2. Possessing complete peripheral blood transcriptome data; 3. No records of concomitant other confirmed liver malignancies; 4. Sample expression data subjected to standardization and quality control. Healthy Control Samples 1. Annotated as healthy individuals in the GEO dataset; 2. No known liver disease or autoimmune disease; 3. Possess complete, qualified transcriptome data.
Exclusion criteria
Exclusion criteria: General Exclusion Criteria 1. Samples lacking critical clinical information (e.g., survival time, survival status); 2. Samples with transcriptomic data quality failing to meet standards or unable to undergo normalization processing; 3. Duplicate samples or technical replicates; 4. Samples with unclear origin or disease diagnosis. Specific Exclusion Criteria for Hepatocellular Carcinoma (HCC) 1. Pathological type is non-hepatocellular carcinoma (e.g., cholangiocarcinoma, mixed-type hepatocellular carcinoma); 2. Patients with concurrent malignant tumors in other systems; 3. Survival follow-up duration is 0 or missing. Specific Exclusion Criteria for Primary Biliary Cholangitis (PBC) 1. Concurrent autoimmune liver disease (e.g., AIH, PSC) where differentiation is impossible; 2. History of confirmed malignancy; 3. Incomplete sample information or abnormal expression data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Risk Score (RS); | — |
Countries
China
Contacts
Public ContactLuo Hongchun
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed